Factor V (F5) HR2 haplotype testing for hypercoagulability
Record ID 32012000579
English
Authors' recommendations:
Hypercoagulability, or thrombophilia, leads to the inappropriate formation of blood clots, and most commonly manifests as venous thromboembolism (VTE), such as deep vein thrombosis (DVT) in the legs or pulmonary embolism (PE). VTE affects approximately 300,000 to 600,000 individuals each year in the United States. Typical precipitating factors for VTE include major trauma, recent surgery, immobilization, medical illness, or aging. Among women, risk is increased during pregnancy and use of oral contraceptives or hormone replacement therapy (HRT). A number of heritable genetic factors also contribute to the risk of VTE; among these is the factor V (F5) gene variant p.Arg506Gln, also known as factor V Leiden (FVL). Recently, a group of linked F5 gene variants collectively known as the HR2 haplotype has been the subject of investigation regarding its association with thrombophilia, alone and in conjunction with p.Arg506Gln (FVL).
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=13739
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Factor V
- Genetic Testing
- Haplotypes
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.